Investors Behind Sprout Accuse Valeant of Bungling Marketing of Female Libido Drug
The investors behind Sprout Pharmaceuticals, the drugmaker that developed what came to be known as "female Viagra" are suing Valeant Pharmaceuticals.
They claim that Valeant failed to commercialize the drug, pushed Sprout into a deal with Valeant's secret pharmacy just days before it faced accusations of fraud, and hiked the drug's price to a point that made it too costly.
Valeant acquired Sprout for $1 billion in August 2015. The deal was struck right after Sprout won approval for Addyi, which intends to treat women with chronically low sex drives, a condition called hypoactive sexual desire disorder (HSDD).
They claim that Valeant failed to commercialize the drug, pushed Sprout into a deal with Valeant's secret pharmacy just days before it faced accusations of fraud, and hiked the drug's price to a point that made it too costly.
Valeant acquired Sprout for $1 billion in August 2015. The deal was struck right after Sprout won approval for Addyi, which intends to treat women with chronically low sex drives, a condition called hypoactive sexual desire disorder (HSDD).